Timbetasin acetate is under clinical development by ReGenTree and currently in Phase III for Keratitis. According to GlobalData, Phase III drugs for Keratitis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Timbetasin acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Timbetasin acetate overview
Timbetasin acetate (RGN-259) is under development for the treatment of neurotrophic keratitis, dry eye associated with GvHD, and moderate to severe dry eye syndrome. The drug candidate is administered as ophthalmic eye drops. The drug candidate is a thymosin beta 4-based product. It was also under development for diabetic retinopathy, and Sjogren's syndrome.
ReGenTree is a biopharmaceutical company which focuses on conducting and funding all clinical trials and product development. The company contributes all of its intellectual property and non-clinical and clinical data generated to date. ReGenTree is headquartered in Princeton, New Jersey, the US.
For a complete picture of Timbetasin acetate’s drug-specific PTSR and LoA scores, buy the report here.